abc biopply ag and Pathways Preclinical Partners (“Path2P”) today announced a new collaboration aimed at enforcing the integration of abc biopply’s cutting-edge preclinical NAM technology 3D CoSeedis within global drug development networks in the US.

The partnership addresses growing demand for self-administered therapies with a scalable, ready-to-use injector platform.

The Swiss healthtech startup’s patented multi-tissue platform aims to make drug discovery faster, safer, and more human-relevant

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancers NOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions in LS carriers Publication in Nature Medicine underscores significance of NOUS-209 clinical data and its innovative approach to inte